

AP-1 Sumoylation site Antibody Blocking Peptide**Synthetic peptide****Catalog # BP2507b****Specification**

AP-1 Sumoylation site Antibody Blocking Peptide - Product Information

Primary Accession

[P05412](#)**AP-1 Sumoylation site Antibody Blocking Peptide - Additional Information****Gene ID** 3725**Other Names**

Transcription factor AP-1, Activator protein 1, AP1, Proto-oncogene c-Jun, V-jun avian sarcoma virus 17 oncogene homolog, p39, JUN

Target/Specificity

The synthetic peptide sequence used to generate the antibody [AP2507b](/product/products/AP2507b) is HPRLQA**LKEE**PQTVPE, containing a predicted sumoylation site from the C-terminal region of human AP-1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

AP-1 Sumoylation site Antibody Blocking Peptide - Protein Information**Name** JUN**Function**

Transcription factor that recognizes and binds to the AP-1 consensus motif 5'-TGA[GC]TCA-3' (PubMed:[10995748](http://www.uniprot.org/citations/10995748), PubMed:[22083952](http://www.uniprot.org/citations/22083952)). Heterodimerizes with proteins of the FOS family to form an AP-1 transcription complex, thereby enhancing its DNA binding activity to the AP-1 consensus sequence 5'-TGA[GC]TCA-3' and enhancing its transcriptional activity (By similarity). Together with FOSB, plays a role in activation-induced cell death of T cells by binding to the AP-1 promoter site of FASLG/CD95L, and inducing its transcription in response to activation of the TCR/CD3 signaling pathway (PubMed:[12618758](http://www.uniprot.org/citations/12618758)). Promotes activity of NR5A1 when phosphorylated by HIPK3 leading to increased steroidogenic gene expression upon cAMP signaling pathway stimulation (PubMed:[12618758](#)).

href="http://www.uniprot.org/citations/17210646" target="_blank">17210646). Involved in activated KRAS-mediated transcriptional activation of USP28 in colorectal cancer (CRC) cells (PubMed:24623306). Binds to the USP28 promoter in colorectal cancer (CRC) cells (PubMed:24623306).

Cellular Location

Nucleus.

Tissue Location

Expressed in the developing and adult prostate and prostate cancer cells.

AP-1 Sumoylation site Antibody Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

AP-1 Sumoylation site Antibody Blocking Peptide - Images**AP-1 Sumoylation site Antibody Blocking Peptide - Background**

The gene for AP-1 is the putative transforming gene of avian sarcoma virus 17. AP-1 is highly similar to the viral protein, and interacts directly with specific target DNA sequences to regulate gene expression. The AP-1 gene is intronless and is mapped to 1p32-p31, a chromosomal region involved in both translocations and deletions in human malignancies. AP-1 dimer activity is downregulated by SUMO-1, SUMO-2, and SUMO-3.

AP-1 Sumoylation site Antibody Blocking Peptide - References

Bossis, et al., Mol Cell Biol. 2005 Aug;25(16):6964-79. Perez-Sala, D., et al., J. Biol. Chem. 278(51):51251-51260 (2003). Yang, H., et al., J. Biol. Chem. 278(51):50887-50896 (2003). Toborek, M., et al., J. Neurochem. 84(1):169-179 (2003). Wang, Y.N., et al., J. Biol. Chem. 278(46):45848-45857 (2003).